Show simple item record

dc.contributor.authorYang, JCH
dc.contributor.authorKim, HR
dc.contributor.authorAhn, MJ
dc.contributor.authorHan, JY
dc.contributor.authorHochmair, MJ
dc.contributor.authorLee, KH
dc.contributor.authorDelmonte, A
dc.contributor.authorCampelo, MRG
dc.contributor.authorKim, DW
dc.contributor.authorFelip, E
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorSpira, A
dc.contributor.authorGettinger, S
dc.contributor.authorTiseo, M
dc.contributor.authorHaney, J
dc.contributor.authorKerstein, D
dc.contributor.authorPopat, S
dc.contributor.authorCamidge, DR
dc.date.accessioned2019-12-09T17:08:12Z
dc.date.available2019-12-09T17:08:12Z
dc.date.issued2019en
dc.identifier.citationYang JCH, Kim HR, Ahn M-J, Han J-Y, Hochmair MJ, Lee KH, et al. O1-4-2 [Encore]Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L. Annals of Oncology. 2019;30(Supplement_6).en
dc.identifier.doi10.1093/annonc/mdz339.006en
dc.identifier.urihttp://hdl.handle.net/10541/622523
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz339.006en
dc.titleBrigatinib (BRG) vs crizotinib (CRZ) in patients (Pts) with ALK inhibitor-naive advanced ALK plus NSCLC from ALTA-1Len
dc.typeMeetings and Proceedingsen
dc.contributor.departmentNational Taiwan University Hospital, Taiwanen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen


This item appears in the following Collection(s)

Show simple item record